Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects

Clinical Endocrinology

Volumn 81, Issue 6, 2014, Pages 862-870

  Lips, Mirjam A ^a   De Groot, Gerrit H ^b   Berends, Frits J ^c   Wiezer, Renee ^c   Van Wagensveld, Bart A ^c   Swank, Dingeman J ^d   Luijten, Arijan ^c   Van Dijk, Ko Willems ^a   Pijl, Hanno ^a   Jansen, Peter L M ^e   Schaap, Frank G ^c,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rode Kruis Hospital   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Dutch Obesity Clinic West   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BILE SALT; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; METFORMIN; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; BLOOD LEVEL; CALORIC RESTRICTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTRIC BANDING; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; LOW CALORY DIET; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ROUX Y ANASTOMOSIS; WEIGHT REDUCTION; BARIATRIC SURGERY; BLOOD; COMPLICATION; MIDDLE AGED; OBESITY, MORBID; PROCEDURES; STOMACH BYPASS;

BARIATRIC SURGERY; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; GASTRIC BYPASS; HUMANS; MIDDLE AGED; OBESITY, MORBID;

EID: 84912526553     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12496     Document Type: Review

References (35)

1. Beenken, A., &, Mohammadi, M., (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov, 8, 235-253.
2. Badman, M.K., Pissios, P., Kennedy, A.R., et al,. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism, 5, 426-437.
3. Dutchak, P.A., Katafuchi, T., Bookout, A.L., et al,. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell, 148, 556-567.
4. Galman, C., Lundasen, T., Kharitonenkov, A., et al,. (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism, 8, 169-174.
5. Kharitonenkov, A., Shiyanova, T.L., Koester, A., et al,. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest, 115, 1627-1635.
6. Chau, M.D., Gao, J., Yang, Q., et al,. (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA, 107, 12553-12558.
7. Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., et al,. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 1542-1546.
8. Dushay, J., Chui, P.C., Gopalakrishnan, G.S., et al,. (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology, 139, 456-463.
9. Jansen, P.L., van Werven, J., Aarts, E., et al,. (2011) Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Digestive Diseases 29, 48-51.
10. Mai, K., Schwarz, F., Bobbert, T., et al,. (2011) Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction. Metabolism, 60, 306-311.
11. Mraz, M., Bartlova, M., Lacinova, Z., et al,. (2009) Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf), 71, 369-375.
12. Kir, S., Beddow, S.A., Samuel, V.T., et al,. (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science, 331, 1621-1624.
13. Cyphert, H.A., Ge, X., Kohan, A.B., et al,. (2012) Activation of the farnesoid x receptor induces hepatic expression and secretion of fibroblast growth factor 21. Journal of Biological Chemistry 287, 25123-25138.
14. Shaham, O., Wei, R., Wang, T.J., et al,. (2008) Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol, 4, 214.
15. Bueter, M., Ashrafian, H., &, le Roux, C.W., (2009) Mechanisms of weight loss after gastric bypass and gastric banding. Obes Facts 232, 5-31.
16. Laferrere, B., Teixeira, J., McGinty, J., et al,. (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 93, 2479-2485.
17. Simonen, M., Dali-Youcef, N., Kaminska, D., et al,. (2012) Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obesity Surgery, 22, 1473-1480.
18. Lips, M.A., de Groot, G.H., van Klinken, J.B., et al,. (2013) Calorie restriction is a major determinant of the short-term metabolic effects of gastric bypass surgery in obese type 2 diabetic patients. Clin Endocrinol (Oxf), 27, 10.
19. Koot, B.G., van der Baan-Slootweg, O.H., Bohte, A.E., et al,. (2013) Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring), 21, 583-590.
20. Schaap, F.G., van der Gaag, N.A., Gouma, D.J., et al,. (2009) High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology, 49, 1228-1235.
21. Mai, K., Bobbert, T., Groth, C., et al,. (2010) Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol Endocrinol Metab, 299, E126-E130.
22. Mashili, F.L., Austin, R.L., Deshmukh, A.S., et al,. (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev, 27, 286-297.
23. Shah, P., Vella, A., Basu, A., et al,. (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 85, 4053-4059.
24. Berglund, E.D., Kang, L., Lee-Young, R.S., et al,. (2010) Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab, 299, E607-E614.
25. Arafat, A.M., Kaczmarek, P., Skrzypski, M., et al,. (2013) Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia, 56, 588-597.
26. Habegger, K.M., Stemmer, K., Cheng, C., et al,. (2013) Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes, 62, 1453-1463.
27. Patti, M.E., Houten, S.M., Bianco, A.C., et al,. (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring), 17, 1671-1677.
28. Pournaras, D.J., Glicksman, C., Vincent, R.P., et al,. (2012) The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology, 153, 3613-3619.
29. Jazet, I.M., Pijl, H., Frolich, M., et al,. (2005) Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism, 54, 705-712.
30. Schaap, F.G., Kremer, A.E., Lamers, W.H., et al,. (2012) Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. Biochimie 95, 692-699.
31. De Sousa-Coelho, A.L., Marrero, P.F., &, Haro, D., (2012) Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J, 443, 165-171.
32. Xu, J., Lloyd, D.J., Hale, C., et al,. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 58, 250-259.
33. Gaich, G., Chien, J.Y., Fu, H., et al,. (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metabolism, 18, 333-340.
34. Matikainen, N., Taskinen, M.R., Stennabb, S., et al,. (2012) Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. European Journal of Endocrinology, 166, 487-492.
35. Kohli, R., Kirby, M., Setchell, K.D., et al,. (2010) Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. American Journal of Physiology. Gastrointestinal and Liver Physiology, 299, G652-G660.